Skip to content

Author

Natalia Gierulska

We have 6 of 16 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Efficacy and Safety of Daraxonrasib (RMC-6236) in Previously Treated Metastatic RAS-Mutated Pancreatic Ductal Adenocarcinoma: A Systematic Review

The results show that daraxonrasib prolonged survival, slowed disease progression and led to tumour shrinkage more frequently than chemotherapy, whilst causing mainly mild, manageable side effects.

Natalia Gierulska, Nina Jankowska, Zuzanna Dąbrowska et al. · 0 citations
Review Open access Sep 2026

Current Evidence and Emerging Directions in Endometriosis Pharmacotherapy: A Systematic Review of Recent Advances

Background: Endometriosis affects 190 million women worldwide, so there is a need for accessible and more comprehensive knowledge regarding the pharmacotherapeutic options that can be offered to patients. This systematic review (2019–2025) synthesizes research results regarding the efficacy and safety of dienogest (DNG...

Zuzanna Betiuk, Martyna Błażyca, Martyna Bartoszczyk et al. · 0 citations
Review Open access Aug 2026

Targeting KRASG12C in non-small cell lung cancer: evidence from randomized clinical trials and future therapeutic strategies

Background The Kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation is no longer an “elusive” target, having become an important therapeutic target in non-small cell lung cancer (NSCLC). The approvals of sotorasib and adagrasib have significantly altered the second-line treatment algorithm. This systemat...

Julia Piekarz, Natalia Picheta, Jakub Pobideł et al. · 0 citations
Review Open access Sep 2026

Refining the TCGA Framework: The Pivotal Role of Targeted Next-Generation Sequencing in Resolving Diagnostic Ambiguities in Endometrial Cancer—Systematic Review

The classification of endometrial cancer based on histological examination often fails to accurately predict treatment outcomes for patients. The Cancer Genome Atlas (TCGA) has proposed a new molecular model that more accurately identifies the tumour subtype, enabling more precise treatment. However, its implementation...

Natalia Gierulska, Julia Orzelska, Katarzyna Lachowska et al. · 0 citations
Review Open access Sep 2026

Prognostic and therapeutic implications of BRCA1 and BRCA2 mutations in ovarian cancer

BRCA1/2 mutation status is a key biomarker in the management of ovarian cancer, supporting personalized treatment strategies and improving patient outcomes, and emerging mechanisms of resistance to PARP inhibitors remain a significant therapeutic challenge.

Weronika Pawul, Paulina Opoka, Agata Dusza et al. · 0 citations
Review Open access Aug 2026

Datopotamab deruxtecan in breast cancer treatment: a systematic review of clinical efficacy and safety

Dato-DXd demonstrates robust clinical activity in patients with BC, providing superior disease control with a favorable safety profile compared to conventional chemotherapy, and preclinical data suggest that the induction of ICD may contribute to reshaping a heterogeneous TME.

Julia Piekarz, Natalia Picheta, Jakub Pobideł et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.